Old Web
English
Sign In
Acemap
>
authorDetail
>
L.I. Chap
L.I. Chap
Medicine
Pathology
Pharmacology
Pharmacokinetics
Bevacizumab
4
Papers
27
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: An economic evaluation
2010
Breast Diseases: A Year Book Quarterly
L.I. Chap
Show All
Source
Cite
Save
Citations (0)
Safety and pharmacokinetics (PK) of AMG 479 in combination with erlotinib (E) or sorafenib (S) in patients (pts) with advanced solid tumors.
2010
Journal of Clinical Oncology
Igor Puzanov
John Sarantopoulos
Jill Gilbert
Devalingam Mahalingam
L.I. Chap
Hongjie Deng
Min Zhu
Ian McCaffery
Gregory Friberg
Lee S. Rosen
Show All
Source
Cite
Save
Citations (6)
Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: An economic evaluation: Dedes KJ, Matter-Walstra K, Schwenkglenks M, et al (Univ Hosp of Zurich, Switzerland; Univ of Basel, Switzerland; et al) Eur J Cancer 45:1397-1406, 2009§
2010
Breast Diseases: A Year Book Quarterly
L.I. Chap
Show All
Source
Cite
Save
Citations (3)
A phase I dose escalation and pharmacokinetic (PK) study of intravenous (iv) aflibercept (VEGF Trap) plus FOLFOX4 in patients (pts) with advanced solid tumors: Preliminary results
2008
Journal of Clinical Oncology
S Limentani
R. Just
A. Purdham
M. Mulay
A. Bair
J. F. Tamby
L.I. Chap
Lee S. Rosen
Show All
Source
Cite
Save
Citations (18)
1